BioCentury
ARTICLE | Financial News

Gene therapy play LogicBio proposes IPO

September 28, 2018 6:03 PM UTC

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan.

LogicBio is developing gene therapies to address rare diseases, particularly rare liver disorders in pediatric patients, using its GeneRide technology. GeneRide uses homologous recombination to link a therapeutic transgene to the endogenous albumin promoter to deliver and integrate genetic material without the use of nucleases. Use of an endogenous promoter minimizes the risk of carcinogenicity caused by added promoters (see "Hitching a (Gene)Ride")...